132 related articles for article (PubMed ID: 11797782)
1. Use of live and inactivated vaccines in the control of West Nile fever in domestic geese.
Malkinson M; Banet C; Khinich Y; Samina I; Pokamunski S; Weisman Y
Ann N Y Acad Sci; 2001 Dec; 951():255-61. PubMed ID: 11797782
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine.
Samina I; Havenga M; Koudstaal W; Khinich Y; Koldijk M; Malkinson M; Simanov M; Perl S; Gijsbers L; Weverling GJ; Uytdehaag F; Goudsmit J
Vaccine; 2007 Nov; 25(49):8338-45. PubMed ID: 17977629
[TBL] [Abstract][Full Text] [Related]
3. An inactivated West Nile virus vaccine for domestic geese-efficacy study and a summary of 4 years of field application.
Samina I; Khinich Y; Simanov M; Malkinson M
Vaccine; 2005 Sep; 23(41):4955-8. PubMed ID: 16023273
[TBL] [Abstract][Full Text] [Related]
4. Protective efficacy of a recombinant subunit West Nile virus vaccine in domestic geese (Anser anser).
Jarvi SI; Lieberman MM; Hofmeister E; Nerurkar VR; Wong T; Weeks-Levy C
Vaccine; 2008 Oct; 26(42):5338-44. PubMed ID: 18723064
[TBL] [Abstract][Full Text] [Related]
5. Inactivated West Nile Virus (WNV) vaccine, Duvaxyn WNV, protects against a highly neuroinvasive lineage 2 WNV strain in mice.
Venter M; van Vuren PJ; Mentoor J; Paweska J; Williams J
Vaccine; 2013 Aug; 31(37):3856-62. PubMed ID: 23820079
[TBL] [Abstract][Full Text] [Related]
6. Protection of red-legged partridges (Alectoris rufa) against West Nile virus (WNV) infection after immunization with WNV recombinant envelope protein E (rE).
Escribano-Romero E; Gamino V; Merino-Ramos T; Blázquez AB; Martín-Acebes MA; de Oya NJ; Gutiérrez-Guzmán AV; Escribano JM; Höfle U; Saiz JC
Vaccine; 2013 Sep; 31(41):4523-7. PubMed ID: 23933372
[TBL] [Abstract][Full Text] [Related]
7. Efficacy study and field application of an inactivated new type gosling viral enteritis virus vaccine for domestic geese.
Chen S; Ma GP; Wang MS; Cheng AC; Zhu DK; Luo QH; Jia RY; Liu F; Chen XY; Han XF; Bo Y; Zhou DC
Poult Sci; 2011 Apr; 90(4):766-74. PubMed ID: 21406361
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, duration, and onset of immunogenicity of a West Nile virus vaccine, live Flavivirus chimera, in horses with a clinical disease challenge model.
Long MT; Gibbs EP; Mellencamp MW; Bowen RA; Seino KK; Zhang S; Beachboard SE; Humphrey PP
Equine Vet J; 2007 Nov; 39(6):491-7. PubMed ID: 18065305
[TBL] [Abstract][Full Text] [Related]
9. Vaccination of captive nēnē (Branta sandvicensis) against West Nile virus using a protein-based vaccine (WN-80E).
Jarvi SI; Hu D; Misajon K; Coller BA; Wong T; Lieberman MM
J Wildl Dis; 2013 Jan; 49(1):152-6. PubMed ID: 23307381
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Cross-Protection of a Lineage 1 West Nile Virus Inactivated Vaccine against Natural Infections from a Virulent Lineage 2 Strain in Horses, under Field Conditions.
Chaintoutis SC; Diakakis N; Papanastassopoulou M; Banos G; Dovas CI
Clin Vaccine Immunol; 2015 Sep; 22(9):1040-9. PubMed ID: 26178384
[TBL] [Abstract][Full Text] [Related]
11. Effect of West Nile virus DNA-plasmid vaccination on response to live virus challenge in red-tailed hawks (Buteo jamaicensis).
Redig PT; Tully TN; Ritchie BW; Roy AF; Baudena MA; Chang GJ
Am J Vet Res; 2011 Aug; 72(8):1065-70. PubMed ID: 21801064
[TBL] [Abstract][Full Text] [Related]
12. The anamnestic serologic response to vaccination with a canarypox virus-vectored recombinant West Nile virus (WNV) vaccine in horses previously vaccinated with an inactivated WNV vaccine.
Grosenbaugh DA; Backus CS; Karaca K; Minke JM; Nordgren RM
Vet Ther; 2004; 5(4):251-7. PubMed ID: 15719324
[TBL] [Abstract][Full Text] [Related]
13. West Nile virus infection in commercial waterfowl operation, Wisconsin.
Meece JK; Kronenwetter-Koepel TA; Vandermause MF; Reed KD
Emerg Infect Dis; 2006 Sep; 12(9):1451-3. PubMed ID: 17073102
[TBL] [Abstract][Full Text] [Related]
14. Domestic goose as a model for West Nile virus vaccine efficacy.
Sá E Silva M; Ellis A; Karaca K; Minke J; Nordgren R; Wu S; Swayne DE
Vaccine; 2013 Feb; 31(7):1045-50. PubMed ID: 23277093
[TBL] [Abstract][Full Text] [Related]
15. A live attenuated West Nile virus strain as a potential veterinary vaccine.
Lustig S; Olshevsky U; Ben-Nathan D; Lachmi BE; Malkinson M; Kobiler D; Halevy M
Viral Immunol; 2000; 13(4):401-10. PubMed ID: 11192286
[TBL] [Abstract][Full Text] [Related]
16. Direct (non-vector) transmission of West Nile virus in geese.
Banet-Noach C; Simanov L; Malkinson M
Avian Pathol; 2003 Oct; 32(5):489-94. PubMed ID: 14522704
[TBL] [Abstract][Full Text] [Related]
17. DNA vaccines encoding the envelope protein of West Nile virus lineages 1 or 2 administered intramuscularly, via electroporation and with recombinant virus protein induce partial protection in large falcons (Falco spp.).
Fischer D; Angenvoort J; Ziegler U; Fast C; Maier K; Chabierski S; Eiden M; Ulbert S; Groschup MH; Lierz M
Vet Res; 2015 Aug; 46(1):87. PubMed ID: 26282836
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacies of three commercially available vaccines against West Nile Virus (WNV) in a short-duration challenge trial involving an equine WNV encephalitis model.
Seino KK; Long MT; Gibbs EP; Bowen RA; Beachboard SE; Humphrey PP; Dixon MA; Bourgeois MA
Clin Vaccine Immunol; 2007 Nov; 14(11):1465-71. PubMed ID: 17687109
[TBL] [Abstract][Full Text] [Related]
19. An outbreak of West Nile virus-associated disease in domestic geese (Anser anser domesticus) upon initial introduction to a geographic region, with evidence of bird to bird transmission.
Austin RJ; Whiting TL; Anderson RA; Drebot MA
Can Vet J; 2004 Feb; 45(2):117-23. PubMed ID: 15025147
[TBL] [Abstract][Full Text] [Related]
20. Equine vaccine for West Nile virus.
Ng T; Hathaway D; Jennings N; Champ D; Chiang YW; Chu HJ
Dev Biol (Basel); 2003; 114():221-7. PubMed ID: 14677692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
